Scarica l'app Stockscreener
0.6469
0.40%
-0.0026
Precedente Chiudi:
$0.6495
Aprire:
$0.65
Volume 24 ore:
59,974
Relative Volume:
0.12
Capitalizzazione di mercato:
$20.44M
Reddito:
$1.22M
Utile/perdita netta:
$-22.43M
Rapporto P/E:
-0.5594
EPS:
-1.1564
Flusso di cassa netto:
$-18.78M
1 W Prestazione:
-7.98%
1M Prestazione:
-11.38%
6M Prestazione:
+4.74%
1 anno Prestazione:
-49.85%
Intervallo 1D:
$0.6304
$0.6712
Intervallo di 1 settimana:
$0.6003
$0.79
Portata 52W:
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.6469 | 20.52M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
523.82 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.12 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
922.76 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
191.72 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
symbol__ Stock Quote Price and Forecast - CNN
Longeveron names Marie Washburn as CFO - MSN
Form 4 Longeveron LLC For: 6 July By Investing.com - Investing.com Canada
Longeveron (NASDAQ: LGVN) CTO has 15,808 shares withheld for taxes - Stock Titan
Longeveron (LGVN) CFO has shares withheld to cover RSU tax obligations - Stock Titan
Longeveron (LGVN) CMO reports 22,505-share tax withholding after RSU vesting - Stock Titan
Longeveron strengthens financial leadership with new CFO appointment - TipRanks
Longeveron Appoints Marie Washburn as Chief Financial Officer - citybiz
New Longeveron (NASDAQ: LGVN) CFO and reverse stock split approval - Stock Titan
Longeveron taps Marie Washburn as CFO ahead of July trial readout - Stock Titan
Price to sales forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to revenue forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Enterprise value to EBITDA forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
Price to earnings forward of Longeveron Inc. – NASDAQ:LGVN - TradingView
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update - The National Law Review
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update - The National Law Review
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Longeveron Inc. Class A Actuals & Estimates (NASDAQ:LGVN) - TradingView
LGVN Forecast — Price Target — Prediction for 2027 - TradingView
LGVN News | LONGEVERON INC-A (NASDAQ:LGVN) - ChartMill
Longeveron Inc (LGVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Longeveron’s Alzheimer’s trial data accepted for poster presentation - Investing.com UK
Longeveron’s Alzheimer’s trial data accepted for poster presentation By Investing.com - Investing.com South Africa
Longeveron to Present Additional Phase 2a Laromestrocel Data in Mild Alzheimer’s Disease at AAIC 2026 - Quiver Quantitative
Longeveron gets AAIC poster slot for Alzheimer’s stem cell data - Stock Titan
New Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC) - The Manila Times
Longeveron Inc (LGVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
Longeveron Inc (LGVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Longeveron Inc (LGVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Longeveron Inc (LGVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Longeveron Inc (LGVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Longeveron Inc (LGVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Longeveron Inc (LGVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesCapex Guidance - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
LGVNLongeveron Inc Stock Price and Quote - Finviz
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.95%
2.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):